Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
7.00
-0.25 (-3.45%)
At close: Feb 21, 2025, 4:00 PM
6.98
-0.02 (-0.27%)
After-hours: Feb 21, 2025, 6:44 PM EST
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $15.43M in the quarter ending September 30, 2024, with 2.28% growth. This brings the company's revenue in the last twelve months to $61.44M, up 6.45% year-over-year. In the year 2023, Ocular Therapeutix had annual revenue of $58.44M with 13.49% growth.
Revenue (ttm)
$61.44M
Revenue Growth
+6.45%
P/S Ratio
15.65
Revenue / Employee
$230,120
Employees
267
Market Cap
1.10B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OCUL News
- 19 days ago - Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - GlobeNewsWire
- 5 weeks ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewsWire
- 7 weeks ago - Ocular Is Now Thoroughly Derisked - Seeking Alpha
- 2 months ago - Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 - GlobeNewsWire
- 3 months ago - Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewsWire
- 3 months ago - Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript - Seeking Alpha